ZL-82 not checked
Chengdu Zenitar Biomedical Technology Co., Ltd
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.”In the company’s words, NCT07193589 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis
- Main trialPhase 2
- “This clinical trial aims to explore whether the drug ZL-82 tablets can be used to treat moderate to severe atopic dermatitis in adults, and to understand the safety and tolerability of the drug. The main questions that the trial intends to answer are: Can ZL-82 tablets alleviate the Eczema Area and Severity Index (EASI) score of patients? What physical problems will patients have after taking ZL-82 tablets? The researchers will compare ZL-82 tablets with placebo (a substance with a similar appearance but without drug components) to observe whether ZL-82 tablets can be used to treat moderate…”In the company’s words, NCT07193589 on ClinicalTrials.gov
Other drugs for Atopic Dermatitis
Coming up1
- 30 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Dec 2027 | A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis | |
| Phase 1Completed | 28 Jan 2024 | Phase I Clinical Study of ZL-82 Tablets | |
| Phase 1Completed | 15 Aug 2024 | ZL-82 Double-blind Clinical Trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026